Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC16A3 | O15427 | 2/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.32 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | MITF | O75030 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25610046 | 0.95 | SLC16A3 (0.33) | SLC16A3SLC16A1MEN1ALDH1A1MAPK1 | |
| SCHEMBL18220183 | 0.93 | MAPT (0.33) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL18220193 | 0.90 | ALDH1A1 (0.34) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL18220209 | 0.86 | PGR (0.31) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL19293946 | 0.86 | MEN1 (0.32) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL18220179 | 0.85 | LMNA (0.46) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL18221386 | 0.85 | PGR (0.30) | PGR | |
| SCHEMBL23134990 | 0.84 | MEN1 (0.36) | SLC16A3SLC16A1MEN1ALDH1A1MAPK1 | |
| SCHEMBL24068151 | 0.83 | MEN1 (0.33) | MEN1ALDH1A1MAPK1KMT2ANPC1 | |
| SCHEMBL18220200 | 0.83 | PGR (0.30) | PGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | SLC16A3 4733/4885SLC16A1 4770/4885MEN1 2997/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | SLC16A3 4733/4885SLC16A1 4770/4885MEN1 2997/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | SLC16A3 4733/4885SLC16A1 4770/4885MEN1 2997/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | SLC16A3 4746/4885SLC16A1 4774/4885MEN1 2973/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | SLC16A3 4746/4885SLC16A1 4774/4885MEN1 2973/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.